# Neural stem cell rejuvenation through single cell pharmacogenomics

> **NIH NIH R01** · UNIVERSITY OF SOUTHERN CALIFORNIA · 2024 · $783,440

## Abstract

PROJECT SUMMARY
 Age is the major risk factor for most chronic human diseases, including Alzheimer’s disease (AD). Neural
stem cells (NSCs) are particularly vulnerable to cellular aging and undergo functional decay in the mature
brain. As a result, adult neurogenesis and its contributions to memory in health and AD are compromised at
early ages. A central goal in regenerative medicine for AD is to determine the factors that rejuvenate
endogenous NSCs and augment cognition. Yet, NSCs are commonly perceived to be a poor target for anti-
aging interventions. A daunting challenge remains for NSC rejuvenation: to restore older NSC proliferation,
increase their numbers, alter NSC fate for neurogenesis and sustain these changes.
 Systems biology offers a potential solution by integrating information from multiple fields. We propose to
develop computational network and pharmacogenomics approaches to prioritize and modulate key age-related
changes for NSC rejuvenation. Our prior work utilized single cell transcriptomics to define molecular cascades
that initiate adult neurogenesis and are compromised during aging. Preliminary data now identifies a new
transition signature that distinguishes quiescent from active NSCs and is altered with age. Our new single cell
pharmacogenomics approach utilizes the transition signature to identify a compound that rejuvenates NSC
function by expanding the NSC pool, increasing neurogenesis and sustaining NSC proliferation. Animal
behavioral studies also demonstrate improved cognition in older mice. Thus, data detailed in this proposal
strongly suggests we can apply combined “omics” approaches to reprogram older NSC function and provide a
new understanding of adult neurogenesis in aging. The mechanisms mediating this NSC reprogramming
remain enigmatic. We will advance the new pharmacogenomics with systems biology techniques in network
connectivity and co-expression to prioritize mechanisms by which NSC aging is reversed (Aim 1), older NSC
function is augmented (Aim 2) and how these changes are sustained (Aim 3).
 Together, this study will reveal evidence of NSC rejuvenation and demonstrate proof-of-principle utility of
new single cell pharmacogenomics and gene networks for enhancing neurogenesis in the aged hippocampus.
These results would provide a paradigm shift in NSC capacity for regeneration, as well as mechanistic insight
into NSC vulnerability to aging, resilience to their decline, and building cognitive reserve.

## Key facts

- **NIH application ID:** 10799587
- **Project number:** 5R01AG076956-03
- **Recipient organization:** UNIVERSITY OF SOUTHERN CALIFORNIA
- **Principal Investigator:** MICHAEL Bonaguidi
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $783,440
- **Award type:** 5
- **Project period:** 2022-06-15 → 2027-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10799587

## Citation

> US National Institutes of Health, RePORTER application 10799587, Neural stem cell rejuvenation through single cell pharmacogenomics (5R01AG076956-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10799587. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*